自噬在急性早幼粒细胞白血病中的研究进展

急性早幼粒细胞白血病（APL）具有特征性的t（15；17）（q22；q21）染色体易位，其表达PML-RARα融合蛋白。全反式维甲酸（ATRA）和三氧化二砷（As2O3）诱导早幼粒白血病细胞分化或凋亡，使APL成为第一种可以治愈的白血病。自噬是维持细胞稳态的重要代谢方式之一，最近有研究显示自噬在ATRA／As2O3诱导治疗中发挥重要作用，而且还可能影响APL对药物诱导凋亡作用的敏感性。因此，今后靶向自噬、调控自噬可能成为APL乃至于其他白血病治疗的一种新手段。对近年来自噬对APL的作用研究进行综述。

Progress of autophagy in acute promyelocytic leukemia

Acute promyelocytic leukemia (APL) is a special subtype of acute myeloid leukemia, characterized by the reciprocal chromosomal translocation of t (15;17)(q22;q21), which generates PML-RARαfusion protein. All-trans-retinoic acid (ATRA) and As2O3 could induce APL cells to differentiation and apoptosis, respectively, making APL become the first curable leukemia. Autophagy is one of metabolic mechanisms to maintain cell homeostasis. Recent studies have showed that autophagy plays an important role in the differentiation of APL cells induced by ATRA/As2O3. Meanwhile, autophagy may affect the sensitivity of APL cells to the pro-apoptotic effect of drugs. Therefore, targeting and regulating autophagy might be a new therapeutic approach of APL and even other leukemia in the future. This article will briefly review the advance of autophagy in APL in recent years.